Previous close | 83.80 |
Open | 84.80 |
Bid | 82.42 x 300 |
Ask | 82.51 x 300 |
Day's range | 82.32 - 84.80 |
52-week range | 76.02 - 99.56 |
Volume | |
Avg. volume | 1,578,650 |
Market cap | 15.654B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 77.77 |
EPS (TTM) | 1.06 |
Earnings date | 29 Jul 2024 - 02 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 110.10 |
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its first-quarter result to...
Insightful Analysis of Biomarin Pharmaceutical Inc's Strengths, Weaknesses, Opportunities, and Threats